Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2023-03-19 Share Issue/Capital Cha…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Notice under Section 708A(5)(e) of the Corporations Act 2 pages 160.3KB
Share Issue/Capital Change Classification · 100% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act, which relates to the issuance of securities without disclosure under Part 6D.2 of the Corporations Act. It provides details about the securities issued, including class, ASX code, date, and number of shares issued. The document is an announcement of a share issue rather than a full financial report or detailed analysis. It does not contain financial statements or substantive financial data but rather informs the market about a capital raising event. Therefore, it fits the category of a Share Issue/Capital Change announcement.
2023-03-19 English
Change of Director's Interest Notice * 5 12 pages 411.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed disclosures of changes in securities holdings by company directors, including acquisitions and disposals of shares, options, and performance rights. It references ASX listing rule 3.19A.2 and section 205G of the Corporations Act, which govern director's interest notifications. The content is focused on personal share transactions by directors, including dates, number of securities before and after changes, and nature of changes such as exercise of performance rights. There is no financial performance data, earnings information, or management discussion. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is substantial and contains multiple such notices for different directors, reinforcing this classification. Therefore, the correct filing type is DIRS (Director's Dealing).
2023-03-19 English
Notification regarding unquoted securities - BOT 7 pages 30.0KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted securities under an employee incentive scheme by Botanix Pharmaceuticals Ltd. It includes specifics such as the number of securities issued, issue dates, security descriptions, and references to ASX listing rules. The content focuses on the announcement of new securities issued, not on financial results, management changes, or other report types. The document length is 6701 characters, which is sufficient to contain substantive details about the securities issuance. Therefore, this document fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other filing types.
2023-03-13 English
Response to ASX Price and Volume Query 4 pages 727.8KB
Regulatory Filings Classification · 95% confidence The document is a letter from ASX Compliance to Botanix Pharmaceuticals Ltd regarding a price query about unusual trading activity in the company's securities. The letter requests information about any undisclosed material information that could explain the trading, compliance with listing rules, and the possibility of a trading halt. The company's response confirms no undisclosed information and compliance with listing rules. This is a regulatory compliance correspondence related to continuous disclosure obligations under ASX Listing Rules, not a financial report, earnings release, or other specific report type. The document is a regulatory filing or announcement related to market compliance and disclosure, fitting the Regulatory Filings (RNS) category.
2023-03-09 English
Webinar Updated Commercial Research for Sofpironium Bromide 17 pages 5.5MB
Investor Presentation Classification · 95% confidence The document is a detailed investor update and commercial research presentation related to Botanix Pharmaceuticals' product Sofpironium Bromide. It includes extensive market research data, patient and physician insights, and strategic commercial information. The document mentions a webinar and a presentation attached to a press release, but the text itself contains substantive content including market analysis, treatment paradigms, and stakeholder receptivity. It is not a brief announcement or a simple notification. There is no indication that this is a full annual or quarterly financial report, audit report, or earnings release. The content is focused on commercial research and investor update, which aligns best with an Investor Presentation (IP) category, as it provides detailed financial and strategic information for investors. The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-03-08 English
Botanix To Host Investor Webinar 2 pages 184.7KB
Investor Presentation Classification · 85% confidence The document is an announcement dated 8 March 2023 about Botanix Pharmaceuticals hosting an investor webinar on 9 March 2023. It describes the webinar's purpose, presenters, registration details, and background information about the company and its products. There is no detailed financial data, no full transcript of the webinar, no financial report, or regulatory filing content. The document is essentially an invitation and informational notice about an upcoming investor presentation event. It does not contain the presentation itself or detailed financial or strategic data typically found in investor presentations. Given the nature of the document as an announcement of an investor webinar and the promise that the presentation will be released later, the best fitting category is Investor Presentation (IP) because the document is focused on the investor presentation event and related information, even though the actual presentation is to be released later. The document is longer than 5,000 characters and contains substantive information about the event and company context, supporting classification as IP rather than a mere announcement (RPA).
2023-03-07 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.